MapLight Therapeutics, Inc.

FWP supplemental

Price $17.00 · 14,750,000 shares · Gross proceeds $258,900,000

424B3 priced

Price $17.00 · 14,750,000 shares · Gross proceeds $250,750,000

8-A12B effective

CERT inactive

S-1/A amended

Price $17.00 · 14,750,000 shares · Gross proceeds $233,197,500

MapLight Therapeutics, Inc. is conducting an initial public offering (IPO) of 14,750,000 shares of common stock at $17.00 per share, with proceeds of $233,197,500. The company, a clinical-stage biopharmaceutical firm, focuses on developing therapies for central nervous system disorders, with its lead candidate ML-007C-MA targeting schizophrenia and Alzheimer’s disease psychosis. The IPO includes a concurrent private placement and underwriting by major firms, with the stock set to list on Nasdaq under 'MPLT'. The company faces risks related to clinical trial outcomes, regulatory approval, and market competition.

FWP supplemental

Price $17.00 · 14,750,000 shares · Gross proceeds $250,750,000

MapLight Therapeutics, Inc. has filed a registration statement on Form S-1 for its initial public offering (IPO) of 14,750,000 shares of common stock at $17.00 per share. The company also plans a concurrent private placement of 476,707 shares to Goldman Sachs affiliates. The IPO is expected to become effective 20 days after filing (October 26, 2025) under Section 8(a) of the Securities Act, with underwriters Morgan Stanley, Jefferies, Leerink Partners, and Stifel managing the offering. The shares will be listed on Nasdaq under 'MPLT'.

S-1 filed

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for debilitating central nervous system (CNS) disorders, including schizophrenia and Alzheimer’s disease psychosis (ADP). The company's lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, designed to address unmet needs in these conditions. The company is conducting Phase 2 trials (ZEPHYR for schizophrenia and VISTA for ADP) and has filed an S-1 registration statement for its initial public offering (IPO), aiming to list on Nasdaq under the symbol MPLT. MapLight is an emerging growth company and smaller reporting company, subject to reduced regulatory reporting requirements.

DRS/A amended

MapLight Therapeutics, Inc. is conducting its initial public offering (IPO) by offering shares of common stock, aiming to list on Nasdaq under the symbol 'MPLT'. The company is a clinical-stage biopharmaceutical firm focused on developing therapies for central nervous system (CNS) disorders, with its lead candidate ML-007C-MA targeting schizophrenia and Alzheimer’s disease psychosis (ADP). The offering includes a fixed-dose combination of a muscarinic agonist and peripherally acting anticholinergic, with Phase 2 trials underway for both indications. The IPO price range and underwriters (Morgan Stanley, Jefferies, Leerink Partners, Stifel) are outlined, though specific figures remain blank.

DRS/A amended

MapLight Therapeutics, Inc. is conducting its initial public offering (IPO) to raise capital for its clinical-stage biopharmaceutical operations. The company focuses on developing therapies for central nervous system (CNS) disorders, with its lead candidate ML-007C-MA targeting schizophrenia and Alzheimer’s disease psychosis. The offering includes voting common stock, with an expected listing on Nasdaq under the symbol MPLT. The company emphasizes its novel muscarinic receptor-targeting approach and highlights ongoing Phase 2 trials for ML-007C-MA.

DRS/A amended

MapLight Therapeutics, Inc. is conducting its initial public offering (IPO) to raise capital for its clinical-stage biopharmaceutical operations. The company focuses on developing therapies for central nervous system (CNS) disorders, with its lead candidate ML-007/PAC targeting schizophrenia and Alzheimer's disease psychosis. The IPO involves offering common stock, with expected listing on Nasdaq under the symbol MPLT. The filing includes details about the underwriters (Morgan Stanley, Jefferies, Leerink Partners, Stifel) and legal counsel (Cooley LLP, Latham & Watkins LLP).

DRS/A amended

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, including schizophrenia and Alzheimer's disease psychosis (ADP). The company is conducting an initial public offering (IPO) to raise capital, with shares expected to be listed on Nasdaq under the symbol MPLT. Its lead candidate, ML-007/PAC, is a fixed-dose combination of a muscarinic agonist and peripherally acting anticholinergic, targeting schizophrenia and ADP. The company also has a second product candidate, ML-004, for autism spectrum disorder (ASD). MapLight is an emerging growth company and smaller reporting company, subject to reduced regulatory reporting requirements.

DRS filed

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, including schizophrenia, Alzheimer's disease psychosis (ADP), and autism spectrum disorder (ASD). The company's lead candidate, ML-007/PAC, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, targeting schizophrenia and ADP. The company plans to list on Nasdaq under the symbol MPLT following its initial public offering (IPO), which aims to raise capital to advance its pipeline, including ML-004 for ASD and preclinical programs for Parkinson's disease and hyperactivity disorders.